San Diego, CA, United States of America

Brad Hehli

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Ambrx, Inc.. Active years: 2015-2019.


% Patents Active = 100.0


 

Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2015-2019

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Brad Hehli

Introduction

Brad Hehli is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of vaccines. With a total of 3 patents to his name, Hehli's work focuses on enhancing vaccine safety and efficacy through innovative methods.

Latest Patents

Hehli's latest patents include groundbreaking work on non-natural amino acid replication-dependent microorganisms and vaccines. These patents detail compositions and methods for producing vaccines that utilize whole organism vaccines with limited replication abilities. This innovative approach aims to increase vaccine safety and efficacy by incorporating non-natural, unnatural, or non-naturally encoded amino acids.

Career Highlights

Hehli is currently associated with Ambrx, Inc., a company known for its advancements in protein therapeutics. His role at Ambrx allows him to leverage his expertise in biotechnology to develop cutting-edge solutions in vaccine production.

Collaborations

Hehli collaborates with Feng Tian, a fellow innovator in the field. Their partnership exemplifies the collaborative spirit that drives innovation in biotechnology.

Conclusion

Brad Hehli's contributions to vaccine development through his innovative patents highlight his role as a key figure in biotechnology. His work continues to pave the way for safer and more effective vaccines, showcasing the importance of innovation in public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…